Literature DB >> 9616163

MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis.

M H Dreyling1, K Schrader, C Fonatsch, B Schlegelberger, D Haase, C Schoch, W Ludwig, H Löffler, T Büchner, B Wörmann, W Hiddemann, S K Bohlander.   

Abstract

The translocation t(10;11)(p13;q14) has been observed in acute lymphoblastic leukemia (ALL) as well as acute myeloid leukemia (AML). A recent study showed a MLL/AF10 fusion in all cases of AML with t(10;11) and various breakpoints on chromosome 11 ranging from q13 to q23. We recently cloned CALM (Clathrin Assembly Lymphoid Myeloid leukemia gene), the fusion partner of AF10 at 11q14 in the monocytic cell line U937. To further define the role of these genes in acute leukemias, 10 cases (9 AML and 1 ALL) with cytogenetically proven t(10;11)(p12-14;q13-21) and well-characterized morphology, immunophenotype, and clinical course were analyzed. Interphase fluorescence in situ hybridization (FISH) was performed with 2 YACs flanking the CALM region, a YAC contig of the MLL region, and a YAC spanning the AF10 breakpoint. Rearrangement of at least one of these genes was detected in all cases with balanced t(10;11). In 4 cases, including 3 AML with immature morphology (1 AML-M0 and 2 AML-M1) and 1 ALL, the signals of the CALM YACS were separated in interphase cells, indicating a translocation breakpoint within the CALM region. MLL was rearranged in 3 AML with myelomonocytic differentiation (2 AML-M2 and 1 AML-M5), including 1 secondary AML. In all 3 cases, a characteristic immunophenotype was identified (CD4+, CD13-, CD33+, CD65s+). AF-10 was involved in 5 of 6 evaluable cases, including 1 case without detectable CALM or MLL rearrangement. In 2 complex translocations, none of the three genes was rearranged. All cases had a remarkably poor prognosis, with a mean survival of 9.6 +/- 6.6 months. For the 7 AML cases that were uniformly treated according to the AMLCG86/92 protocols, disease-free and overall survival was significantly worse than for the overall study group (P = .03 and P = .01, respectively). We conclude that the t(10;11)(p13;q14) indicates CALM and MLL rearrangements in morphologically distinct subsets of acute leukemia and may be associated with a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9616163

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Authors:  Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal
Journal:  Blood Adv       Date:  2018-12-11

Review 2.  Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors:  Kelly Faulk; Lia Gore; Todd Cooper
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

Review 3.  Unconventional functions for clathrin, ESCRTs, and other endocytic regulators in the cytoskeleton, cell cycle, nucleus, and beyond: links to human disease.

Authors:  Frances M Brodsky; R Thomas Sosa; Joel A Ybe; Theresa J O'Halloran
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-02       Impact factor: 10.005

4.  The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest.

Authors:  Raouf Ben Abdelali; Vahid Asnafi; Arnaud Petit; Jean-Baptiste Micol; Céline Callens; Patrick Villarese; Eric Delabesse; Oumedaly Reman; Stephane Lepretre; Jean-Yves Cahn; Gaelle Guillerm; Céline Berthon; Claude Gardin; Bernadette Corront; Thibaut Leguay; Marie-Christine Béné; Norbert Ifrah; Guy Leverger; Hervé Dombret; Elizabeth Macintyre
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

5.  The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models.

Authors:  S Dutta; A Krause; S Vosberg; T Herold; B Ksienzyk; L Quintanilla-Martinez; B Tizazu; M Chopra; A Graf; S Krebs; H Blum; P A Greif; A Vetter; K Metzeler; M Rothenberg-Thurley; M R Schneider; M Dahlhoff; K Spiekermann; U Zimber-Strobl; E Wolf; S K Bohlander
Journal:  Leukemia       Date:  2015-12-21       Impact factor: 11.528

6.  The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/β-catenin coactivators essential for intestinal homeostasis.

Authors:  Tokameh Mahmoudi; Sylvia F Boj; Pantelis Hatzis; Vivian S W Li; Nadia Taouatas; Robert G J Vries; Hans Teunissen; Harry Begthel; Jeroen Korving; Shabaz Mohammed; Albert J R Heck; Hans Clevers
Journal:  PLoS Biol       Date:  2010-11-16       Impact factor: 8.029

7.  A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis.

Authors:  Amanda E Conway; Paula B Scotland; Catherine P Lavau; Daniel S Wechsler
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

8.  The CALM and CALM/AF10 interactor CATS is a marker for proliferation.

Authors:  Leticia Fröhlich Archangelo; Philipp A Greif; Michael Hölzel; Thomas Harasim; Elisabeth Kremmer; Gerhard K H Przemeck; Dirk Eick; Aniruddha Jayant Deshpande; Christian Buske; Martin Hrabé de Angelis; Sara Teresinha Olalla Saad; Stefan K Bohlander
Journal:  Mol Oncol       Date:  2008-09-04       Impact factor: 6.603

9.  Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice.

Authors:  David Caudell; Zhenhua Zhang; Yang Jo Chung; Peter D Aplan
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

10.  Identification of novel Myc target genes with a potential role in lymphomagenesis.

Authors:  Dragan Marinkovic; Tatjana Marinkovic; Eniko Kokai; Thomas Barth; Peter Möller; Thomas Wirth
Journal:  Nucleic Acids Res       Date:  2004-10-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.